Skip to content

Clinical application and related pathological study of contrast-enhanced ultrasound in diabetes nephropathy

Clinical application and related pathological study of contrast-enhanced ultrasound in diabetes nephropathy

Status
Recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2400082889
Enrollment
Unknown
Registered
2024-04-10
Start date
2024-01-19
Completion date
Unknown
Last updated
2024-04-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

diabetes nephropathy

Interventions

Gold Standard:Pathological examination of renal puncture tissue

Sponsors

China Japan Friendship Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: a. The patient agrees to undergo contrast-enhanced ultrasound and kidney puncture examination and signs an informed consent form; b. Diabetes nephropathy is clinically suspected. c. No abnormalities were found in the spleen.

Exclusion criteria

Exclusion criteria: a. Renal space occupying lesions; b. Middle renal parenchyma with cysts larger than 3.0cm; c. Polycystic kidney; d. Renal artery stenosis or renal vein thrombosis; e. Hydronephrosis; f. Sponge kidney; g. The patient has contraindications for renal biopsy or contrast-enhanced ultrasound (refer to relevant guidelines); h. The patient has a walnut cracker phenomenon.

Design outcomes

Primary

MeasureTime frame
fibrosis area;microvessel density;Peak Echo Intensity;The correlation coefficient between fibrosis area and peak echo intensity;The correlation coefficient between microvascular density and peak echo intensity;

Countries

CHINA

Contacts

Public ContactJingping Wu

China Japan Friendship Hospital

1098183571@qq.com+86 137 1807 2497

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026